FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589056662> ?p ?o ?g. }

• W2589056662 abstract "Abstract Abstract 1865 Background: The three drugs combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) has been proven to be a powerful regimen for the treatment of the patients with multiple myeloma (MM). However, twice-weekly schedule of bortezomib and high dose dexamethasone has been shown to cause significant toxicities, including severe peripheral neuropathy (PN). Recently, once-weekly bortezomib induction therapy with CyBorD (modified-CyBorD) has shown less toxicity with high response rate equal to original regimen (Reeder, CB et al. Leukemia 2009). However, more than half of the patients developed bortezomib induced PN (BiPN) in modified-CyBorD. Thus it was still concerned adverse event for the transplant ineligible patients, especially frail elderly patients because it often caused interruption or withdrawal of the treatments, resulting in fewer efficacies. Under these circumstances, we introduced the reduced-dosage of CyBorD regimen (reduced-CyBorD) in the transplant ineligible patients with multiple myeloma for continuation of the treatment. Methods: The protocol consisted of bortezomib given intravenously at a dose of 1.3 mg/m2once a week on days 1, 8, 15, cyclophosphamide orally at a dose of 50 mg daily on days 1–21, and dexamethasone orally or intravenously at a dose of 20 mg daily on days 1,2,8,9,15,16 in 4-week cycles. Total of 20 patients, including 12 newly diagnosed and 8 refractory, were treated with reduced-CyBorD and evaluated its efficacy and safety. Results: The median age was 72 years (range from 62 to 81). 14 patients were more than 70 year-old (70%). A half of the patients were female. According ISS, 3 patients were classified in stage I, 6 were in II, and 11 were in III. The overall response was 86.6 % with 26.7 % CR/nCR (1 CR, 3 nCR, 5 VGPR and 4 PR). Hematological adverse events were neutropenia (35%; G1/2 n=7), lymphocytopenia (35%; G1/2 n=1, G3/4, n=1), thrombocytopenia (10%; G1/2 n=2). Non-hematological adverse events were pneumonia (20%; G2 n=2, G3 n=2), VZV infection (15%; G2 n=3), cerebral infarction (5%; G2 n=1). Importantly, only three patients (15%) developed grade 1 PN, and no patient reduced or discontinued bortezomib due to PN. Conclusions: Reduced-CyBorD with three times once-weekly bortezomib retained high efficacy seen in standard and modified CyBorD (4 times bortezomib administration). Furthermore, it was found that this regimen obviously revealed less toxicity, especially BiPN compared with those previous regimens (See Table). Our results suggested that reduced-CyBorD might be safe and effective approach to the transplant ineligible patients, especially elderly frail patients with MM. Disclosures: No relevant conflicts of interest to declare." @default.
• W2589056662 created "2017-02-24" @default.
• W2589056662 creator A5000321737 @default.
• W2589056662 creator A5016164244 @default.
• W2589056662 creator A5024216161 @default.
• W2589056662 creator A5038063905 @default.
• W2589056662 creator A5049643676 @default.
• W2589056662 creator A5054154742 @default.
• W2589056662 creator A5068192162 @default.
• W2589056662 creator A5075218181 @default.
• W2589056662 date "2012-11-16" @default.
• W2589056662 modified "2023-09-27" @default.
• W2589056662 title "Reduced-Dosage of Three Drugs Combination of Cyclophosphamide, Bortezomib and Dexamethasone (reduced-CyBorD) Retains High Response Rate with Less Toxicities in Elderly Patients with Multiple Myeloma" @default.
• W2589056662 doi "https://doi.org/10.1182/blood.v120.21.1865.1865" @default.
• W2589056662 hasPublicationYear "2012" @default.
• W2589056662 type Work @default.
• W2589056662 sameAs 2589056662 @default.
• W2589056662 citedByCount "1" @default.
• W2589056662 countsByYear W25890566622018 @default.
• W2589056662 crossrefType "journal-article" @default.
• W2589056662 hasAuthorship W2589056662A5000321737 @default.
• W2589056662 hasAuthorship W2589056662A5016164244 @default.
• W2589056662 hasAuthorship W2589056662A5024216161 @default.
• W2589056662 hasAuthorship W2589056662A5038063905 @default.
• W2589056662 hasAuthorship W2589056662A5049643676 @default.
• W2589056662 hasAuthorship W2589056662A5054154742 @default.
• W2589056662 hasAuthorship W2589056662A5068192162 @default.
• W2589056662 hasAuthorship W2589056662A5075218181 @default.
• W2589056662 hasConcept C126322002 @default.
• W2589056662 hasConcept C141071460 @default.
• W2589056662 hasConcept C197934379 @default.
• W2589056662 hasConcept C2776364478 @default.
• W2589056662 hasConcept C2776694085 @default.
• W2589056662 hasConcept C2776755627 @default.
• W2589056662 hasConcept C2777478702 @default.
• W2589056662 hasConcept C2780401358 @default.
• W2589056662 hasConcept C2781413609 @default.
• W2589056662 hasConcept C71924100 @default.
• W2589056662 hasConcept C90924648 @default.
• W2589056662 hasConceptScore W2589056662C126322002 @default.
• W2589056662 hasConceptScore W2589056662C141071460 @default.
• W2589056662 hasConceptScore W2589056662C197934379 @default.
• W2589056662 hasConceptScore W2589056662C2776364478 @default.
• W2589056662 hasConceptScore W2589056662C2776694085 @default.
• W2589056662 hasConceptScore W2589056662C2776755627 @default.
• W2589056662 hasConceptScore W2589056662C2777478702 @default.
• W2589056662 hasConceptScore W2589056662C2780401358 @default.
• W2589056662 hasConceptScore W2589056662C2781413609 @default.
• W2589056662 hasConceptScore W2589056662C71924100 @default.
• W2589056662 hasConceptScore W2589056662C90924648 @default.
• W2589056662 hasLocation W25890566621 @default.
• W2589056662 hasOpenAccess W2589056662 @default.
• W2589056662 hasPrimaryLocation W25890566621 @default.
• W2589056662 hasRelatedWork W2097007321 @default.
• W2589056662 hasRelatedWork W2156708376 @default.
• W2589056662 hasRelatedWork W2290543497 @default.
• W2589056662 hasRelatedWork W2340210278 @default.
• W2589056662 hasRelatedWork W2352427406 @default.
• W2589056662 hasRelatedWork W2554908277 @default.
• W2589056662 hasRelatedWork W2555294339 @default.
• W2589056662 hasRelatedWork W2561018524 @default.
• W2589056662 hasRelatedWork W2570467653 @default.
• W2589056662 hasRelatedWork W2570571228 @default.
• W2589056662 hasRelatedWork W2586850755 @default.
• W2589056662 hasRelatedWork W2588275579 @default.
• W2589056662 hasRelatedWork W2588946684 @default.
• W2589056662 hasRelatedWork W2591725776 @default.
• W2589056662 hasRelatedWork W2592592385 @default.
• W2589056662 hasRelatedWork W2915869410 @default.
• W2589056662 hasRelatedWork W2960209344 @default.
• W2589056662 hasRelatedWork W2980472107 @default.
• W2589056662 hasRelatedWork W2981246357 @default.
• W2589056662 hasRelatedWork W68159190 @default.
• W2589056662 isParatext "false" @default.
• W2589056662 isRetracted "false" @default.
• W2589056662 magId "2589056662" @default.
• W2589056662 workType "article" @default.